Avalo Therapeutics (AVTX) Current Assets (2014 - 2026)
Avalo Therapeutics posted quarterly Current Assets of $88.8 million for Q1 2026, down 30.03% year-on-year from $126.9 million in Q1 2025, and down 15.63% on a QoQ basis from $105.3 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Current Assets data on file, last reported at $88.8 million in Q1 2026.
- For the quarter ending Q1 2026, Current Assets fell 30.03% year-over-year to $88.8 million; the trailing twelve-month figure through Mar 2026 stood at $88.8 million (down 30.03% YoY), and the FY2025 full-year result was $105.3 million, down 24.19% from the prior year.
- Current Assets for Q1 2026 stood at $88.8 million, down from $105.3 million in the prior quarter.
- Across five years, Current Assets topped out at $138.9 million in Q4 2024 and bottomed at $7.5 million in Q2 2023.
- The 5-year median for Current Assets is $86.1 million (2024), against an average of $66.2 million.
- The widest annual swing landed in 2022, when Current Assets slumped 74.74%; it then jumped 1554.44% in 2024.
- A 5-year view of Current Assets shows it stood at $16.4 million in 2022, then plunged by 48.86% to $8.4 million in 2023, then surged by 1554.44% to $138.9 million in 2024, then retreated by 24.19% to $105.3 million in 2025, then fell by 15.63% to $88.8 million in 2026.
- The last three Current Assets figures came in at $88.8 million (Q1 2026), $105.3 million (Q4 2025), and $113.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 88.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.83 Mn |
| Dec 31, 2025 | 105.29 Mn |
| Sep 30, 2025 | 113.85 Mn |
| Jun 30, 2025 | 115.19 Mn |
| Mar 31, 2025 | 126.94 Mn |
| Dec 31, 2024 | 138.89 Mn |
| Sep 30, 2024 | 86.15 Mn |
| Jun 30, 2024 | 95.89 Mn |
| Mar 31, 2024 | 111.21 Mn |
| Dec 31, 2023 | 8.40 Mn |
| Sep 30, 2023 | 12.66 Mn |
| Jun 30, 2023 | 7.52 Mn |
| Mar 31, 2023 | 19.25 Mn |
| Dec 31, 2022 | 16.42 Mn |
| Sep 30, 2022 | 19.45 Mn |
| Jun 30, 2022 | 15.02 Mn |
| Mar 31, 2022 | 43.66 Mn |
| Dec 31, 2021 | 61.85 Mn |
| Sep 30, 2021 | 77.01 Mn |
| Jun 30, 2021 | 47.36 Mn |
| Mar 31, 2021 | 46.10 Mn |
| Dec 31, 2020 | 26.01 Mn |
| Sep 30, 2020 | 41.03 Mn |
| Jun 30, 2020 | 50.24 Mn |
| Mar 31, 2020 | 25.49 Mn |
| Dec 31, 2019 | 17.72 Mn |
| Sep 30, 2019 | 12.59 Mn |
| Jun 30, 2019 | 13.90 Mn |
| Mar 31, 2019 | 26.74 Mn |
| Dec 31, 2018 | 21.93 Mn |
| Sep 30, 2018 | 18.47 Mn |
| Jun 30, 2018 | 11.84 Mn |
| Mar 31, 2018 | 13.39 Mn |
| Dec 31, 2017 | 10.67 Mn |
| Sep 30, 2017 | 28.11 Mn |
| Jun 30, 2017 | 5.95 Mn |
| Mar 31, 2017 | 3.46 Mn |
| Dec 31, 2016 | 5.66 Mn |
| Sep 30, 2016 | 9.49 Mn |
| Jun 30, 2016 | 13.13 Mn |
| Mar 31, 2016 | 16.89 Mn |
| Dec 31, 2015 | 21.62 Mn |
| Sep 30, 2015 | 3.41 Mn |
| Dec 31, 2014 | 12.16 Mn |